June 1, 2020
Ricardo Parker, PhD, Joins SageMedic's Scientific Advisory Board
SageMedic is pleased to announce that Ricardo Parker, PhD, Associate Professor, Department of Health Sciences, National University, has joined our Scientific Advisory Board. Ricardo has been a Senior Scientist and Director of Research at Exiqon (formerly Oncotech, Inc.), a well-known entity to experts in the field that has developed and successfully commercialized the extreme drug resistance (EDR) assay for thousands of cancer patients. Ricardo holds a BS in biology from the Shaw University in Raleigh, NC, a MS in biology from the Tennessee State University, TE, and a PhD in microbiology from the Oregon State University, OR.
May 8, 2020
Dr. Benjamin Krantz, MD, MBA, Joins SageMedic's Scientific Advisory Board
SageMedic is pleased to announce that Benjamin Krantz MD, MBA, has joined our Scientific Advisory Board. Dr. Krantz is a fellow in hematology/oncology at New York University Langone Medical Center and serves on the Board of Directors of Advance Proteome Therapeutics, NY.
He completed his residency in internal medicine at New York-Presbyterian Hospital – Columbia University Medical Center during which time he analyzed investigator intellectual property disclosures as a Columbia Technology Ventures fellow. He subsequently worked as a hospitalist and clinical/translational researcher at Memorial Sloan Kettering Cancer Center. His research has focused on biomarker and therapeutic development in pancreas ductal adenocarcinoma. He has authored peer-reviewed articles on novel therapeutics for pancreas cancer and emerging biomarkers for therapeutic selection. He has also been the architect of investigational protocols for the development of new pancreas cancer biomarkers and an early phase therapeutic candidate. Ben received a Bachelor of Arts from the University of Pennsylvania and received his Doctor of Medicine and Masters of Business Administration in Healthcare from Tufts University.
March 6, 2020
Dr. Mona Wood, MD, PhD, Joins SageMedic as the Medical Lab Director
SageMedic is pleased to announce that Mona Wood, MD, PhD, has joined as our Medical Lab Director overseeing quality control and establishing CLIA certification for SageMedic.
Dr. Wood is a Stanford trained pathologist with over 15 years of experience in biomedical research in a variety of scientific fields including gene therapy, protein structure and computational chemistry. She has earned numerous research awards and grants, including an independent early-investigator training award from NIH’s National Cancer Institute. She has served as an elected chief resident in pathology informatics for two academic years at Stanford and is a graduate of Stanford’s Biodesign Innovation course. She majored in Chemistry, Biochemistry and French at the University of Michigan and received her MD and PhD in Chemistry from the University of California, Irvine.
January 7-10, 2019
JP Morgan Healthcare Conference Week
SageMedic will present at the Biotech Showcase associated with the JP Morgan Healthcare Conference week. The presentation is scheduled for January 8, 2019 at 10:15 am. Qualified investors may review our technology and meet with our top management. Contact Suzie Thigpen to arrange a meeting at
October 30, 2018
SageMedic Presents at NYC Oncology Conference
SageMedic presented to the NYC Oncology Conference where the latest developments in oncology and a select group of exceptional investment opportunities in precision medicine, diagnostics, etc. present. Key opinion leaders in the field of oncology, as well as life science investors led discussions on challenges and opportunities in oncology.
August 3, 2018
Dr. Apfel, CEO of SageMedic, Interviews at Nasdaq Market Site
August 22-24, 2018
SageMedic Presents at Keiretsu Northern California Chapter
Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists and corporate/institutional investors. Because Keiretsu Forum was SageMedic's Seed round audience, where SageMedic received so much attention and was oversubscribed. It only made sense to bring the Keiretsu members the Bridge round opportunity before SageMedic moved on to the Series A round.
August 23, 2018
SageMedic Awarded "Most Valuable Company" Award at Keiretsu Pacific Northwest Capital Expo
SageMedic was well received and really got the audience interested in functional precision medicine. With an excellent presentation and interaction throughout the night, SageMedic was able to keep the topic hot and was voted the Most Valuable Company by the audience.
August 23, 2018
SageMedic Presents at Keiretsu Pacific NorthWest Capital Expo, Washington
Keiretsu forum was SageMedic's Seed round audience, where SageMedic received so much attention and was oversubscribed. It only made sense to bring the Keiretsu members the Bridge round opportunity before SageMedic moved on to the Series A round.
May 6, 2018
SageMedic Presents at NYC Oncology Conference
NYC Oncology is a conference where the latest developments in oncology and a select group of exceptional investment opportunities in precision medicine, diagnostics, etc. present. Key opinion leaders in the field of oncology, as well as life science investors will lead discussions on challenges and opportunities in oncology. SageMedic presented the end of the Seed round at this conference.
March 26, 2018
SageMedic is a Finalist at LyfeBulb-Helsinn Innovation Summit
SageMedic was selected as one of the finalists of the Lyfebulb/Helsinn Innovation Summit in Monte-Carlo, Monaco, March 26, 2018, with all travel expenses paid.
SageMedic Selected to Present at Swedish American Life Science Summit
May 7—9, 2017
SageMedic Selected to Present at Cavendish Global Health Impact Forum
The Forum provides an environment for family offices, foundations and impact investors to develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. Michael Moffat, Cavendish co-founder and Chairman explains, “The quality and originality of SageMedic’s research and scientific insights in 3D micro-tumor assays positions them to make a major contribution to improving patient outcomes by giving physicians the data they need to make better informed cancer treatment decisions.”